相关实验视频

Updated: Jun 23, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

RPN1:一种泛癌生物标志物和二硫化调节剂

Xing Wang^1,2, Hong-Quan Zhu², Shi-Ming Lin²

¹Department of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.

Translational cancer research

|June 17, 2024

概括

利博林I (RPN1) 通过分解细胞骨架来促进脱硫化. RPN1显示出作为泛癌生物标志物的潜力,并预测免疫治疗反应,为癌症治疗提供新的途径.

科学领域:

细胞生物学细胞生物学
癌症研究癌症研究
分子瘤学分子瘤学

背景情况:

细胞死亡模式 - - 脱硫脱症与SLC7A11表达和葡萄糖剥夺有关.
不同瘤细胞系中二硫化的患病率尚未完全理解.
里博林I (RPN1) 基因被删除会产生对二硫化的抗性,但其机制尚不清楚.

研究的目的:

阐明RPN1诱导二硫化的机制.
研究RPN1作为泛癌生物标志物的潜力.
探索RPN1在瘤微环境中的作用及其与免疫治疗的关联.

主要方法:

实验验证使用流细胞计,免疫光和西部斑点.
来自公共数据库 (例如,GEO) 的瘤组织中RPN1表达的生物信息分析.
对RPN1表达与临床相关性,瘤微环境因素和免疫治疗反应的相关性分析.

主要成果:

发现RPN1主要通过乳腺癌和肺癌细胞系的细胞骨分解来诱导二硫化.
在许多固体瘤中,RPN1表现出广泛的mRNA表达,并显示出显著的诊断潜力,特别是在质母细胞瘤中.
在不同类型的癌症中,RPN1表达与不同的整体生存结果相关,并且与免疫细胞透和抗PD-L1治疗在泌尿腺癌中的疗效有关.

结论:

通过细胞骨架的破坏,RPN1在调解脱硫化症方面发挥着至关重要的作用.
RPN1作为一个相关的泛癌生物标志物,具有预后影响.
RPN1与免疫相关途径有关,可以预测对抗PD-L1免疫疗法的反应.

关键词:

脱硫脱症是一种脱硫脱症.在 SLC7A1111 中.反编程细胞死亡配体1 (抗PD-L1) 的抗编程细胞死亡配体1.胰腺癌是一种癌症.里波林 I (RPN1) 是一种

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...